Interpharm Holdings, Inc. (IPAH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInterpharm Holdings, Inc. (IPAH) trades at $0.00001. Interpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter pharmaceuticals, supplying major retailers, wholesalers, and managed care organizations. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for IPAH: IPAH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Interpharm Holdings, Inc. (IPAH) Healthcare & Pipeline Overview
Interpharm Holdings, Inc., founded in 1984, develops, manufactures, and markets generic prescription and over-the-counter pharmaceuticals. The company supplies major retailers, wholesalers, managed care organizations, and national distributors. Operating within the healthcare sector, Interpharm faces competition in the generic pharmaceutical market, with a focus on cost-effective medicine distribution.
What Is the Investment Thesis for IPAH?
Interpharm Holdings, Inc. operates in the generic pharmaceutical market, characterized by high competition and pricing pressures. With a market capitalization of $0.00B and a negative P/E ratio of -0.02, the company's financial performance requires careful consideration. A gross margin of 28.7% indicates some ability to control production costs, but a negative profit margin of -18.6% raises concerns about overall profitability. Potential catalysts include expanding its product portfolio and distribution network. However, the company faces risks related to regulatory changes, competition, and pricing pressures. The negative beta of -120.16 suggests an inverse correlation with the market, which could provide some downside protection during market downturns. Investors should closely monitor the company's ability to improve profitability and manage its operational costs. The lack of dividend yield may deter income-focused investors.
Based on FMP financials and quantitative analysis
IPAH Key Highlights
Market capitalization of $0.00B indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.02 reflects current losses, requiring investors to focus on future earnings potential.
- Gross margin of 28.7% shows the company's ability to generate revenue from sales after deducting the cost of goods sold.
- Negative profit margin of -18.6% highlights the company's struggle to achieve profitability, indicating high operating expenses or other financial challenges.
- Beta of -120.16 suggests the stock price moves inversely to the market, potentially offering diversification benefits.
Who Are IPAH's Competitors?
IPAH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IPAH's Key Strengths?
Established distribution network.
- Expertise in generic pharmaceutical development.
- Focus on cost-effective solutions.
- Long-standing presence in the market.
What Are IPAH's Weaknesses?
Negative profit margin (-18.6%).
- Limited product diversification.
- Small market capitalization ($0.00B).
- Dependence on generic drug market.
What Are the Key Risks for IPAH?
Financial-distress signal — its Altman Z-Score of -1.12 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-82.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the generic pharmaceutical market could lead to pricing pressures.
- Regulatory changes and compliance requirements could increase operational costs.
- Patent expirations and intellectual property risks could impact product portfolio.
- Negative profit margin (-18.6%) indicates financial instability.
- Limited financial disclosure due to OTC Other tier status increases investment risk.
What Are IPAH's Competitive Advantages?
- Established distribution network with major retailers and wholesalers.
- Expertise in generic pharmaceutical development and manufacturing.
- Focus on cost-effective medicine options.
- Long-standing presence in the pharmaceutical market (founded in 1984).
What Does IPAH Do?
Interpharm Holdings, Inc., established in 1984, is a pharmaceutical company focused on the development, manufacture, and marketing of generic prescription strength and over-the-counter (OTC) pharmaceuticals. Headquartered in Hauppauge, New York, the company has built a business model centered around providing affordable medicine options to a broad customer base. Interpharm supplies its products to major retailers, wholesalers, managed care organizations, and national distributors, ensuring wide availability of its pharmaceutical offerings. The company's product portfolio includes a range of generic drugs, designed to offer cost-effective alternatives to brand-name medications. By focusing on generics, Interpharm aims to address the growing demand for affordable healthcare solutions. The company's operations encompass the entire pharmaceutical value chain, from product development and manufacturing to marketing and distribution. This integrated approach allows Interpharm to maintain control over quality and cost, enhancing its competitiveness in the market. Interpharm's strategy is to continue expanding its product portfolio and distribution network, solidifying its position as a key player in the generic pharmaceutical industry. As of 2026, Interpharm faces the challenges and opportunities inherent in the evolving healthcare landscape, including regulatory changes, pricing pressures, and increasing competition.
What Products and Services Does IPAH Offer?
- Develops generic prescription-strength pharmaceuticals.
- Manufactures over-the-counter (OTC) medications.
- Markets pharmaceutical products to various healthcare providers.
- Supplies medicines to major retailers and wholesalers.
- Distributes products to managed care organizations.
- Provides pharmaceuticals to national distributors.
- Focuses on cost-effective medicine options.
How Does IPAH Make Money?
- Develops and manufactures generic pharmaceuticals.
- Markets and distributes products through various channels.
- Generates revenue through the sale of prescription and OTC drugs.
- Focuses on supplying affordable medicine options.
What Industry Does IPAH Operate In?
Interpharm Holdings, Inc. operates within the medical-pharmaceuticals industry, a sector characterized by intense competition and regulatory scrutiny. The market is driven by an aging population, increasing prevalence of chronic diseases, and growing demand for affordable healthcare solutions. Generic drug manufacturers like Interpharm play a crucial role in providing cost-effective alternatives to brand-name medications. The industry faces challenges such as pricing pressures, patent expirations, and evolving regulatory landscapes. Competitors such as CBGL, DNAG, IMMB, INLB, and JNHMF operate in this space, each vying for market share. Growth opportunities exist through product innovation, strategic partnerships, and expansion into new markets.
Who Are IPAH's Key Customers?
- Major retailers (e.g., pharmacies, supermarkets).
- Wholesalers (e.g., pharmaceutical distributors).
- Managed care organizations (e.g., HMOs, PPOs).
- National distributors (e.g., large-scale pharmaceutical suppliers).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Interpharm Holdings, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Hauppauge, US. The company is led by CEO Raj Sutaria. IPAH has traded publicly since 2000.
Key Financial Metrics
Return on equity for Interpharm Holdings, Inc. stands at -82.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.9%, showing how much profit it generates from its asset base. A current ratio of 1.05 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Interpharm Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.12 places it in the distress zone, a signal of elevated financial risk.
IPAH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IPAH Latest News
No recent news available for IPAH.
IPAH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IPAH.
Price Targets
Wall Street price target analysis for IPAH.
IPAH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IPAH; grades run from A+ (80-100) to F (below 30).
Leadership: Raj Sutaria
CEO
Raj Sutaria serves as the CEO of Interpharm Holdings, Inc., overseeing the company's strategic direction and operational execution. With extensive experience in the pharmaceutical industry, Sutaria has held various leadership roles in product development, marketing, and sales. His background includes a strong understanding of generic drug manufacturing, regulatory compliance, and market dynamics. Sutaria's expertise lies in driving growth, improving operational efficiency, and fostering a culture of innovation within the organization. He is committed to delivering affordable and accessible healthcare solutions to patients.
Track Record: Under Raj Sutaria's leadership, Interpharm Holdings, Inc. has focused on expanding its product portfolio and strengthening its distribution network. Key achievements include the successful launch of several new generic drugs and the establishment of strategic partnerships with major retailers and wholesalers. Sutaria has also prioritized improving manufacturing efficiency and reducing operational costs. His strategic decisions have helped the company navigate the challenges of the competitive pharmaceutical market and maintain a strong position in the industry.
IPAH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Interpharm Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, which can lead to greater information asymmetry and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares at desired prices.
- OTC Other companies face less regulatory oversight, increasing the potential for fraud or manipulation.
- The company may not meet the minimum financial standards of higher-tier exchanges, indicating financial instability.
- Potential for delisting or trading suspension due to non-compliance with OTC market regulations.
- Verify the company's registration and compliance status with the SEC and OTC Markets Group.
- Obtain and review any available financial statements, including balance sheets, income statements, and cash flow statements.
- Assess the company's management team and their experience in the pharmaceutical industry.
- Research the company's products and market position, including its competitive landscape and growth potential.
- Evaluate the company's legal and regulatory risks, including potential liabilities and compliance issues.
- Monitor trading volume and price volatility to assess liquidity and potential for price manipulation.
- Consult with a qualified financial advisor before making any investment decisions.
- The company was founded in 1984, indicating a long-standing presence in the pharmaceutical market.
- Interpharm supplies its medicines to major retailers, wholesalers, and managed care organizations, suggesting established business relationships.
- The company has 670 employees, implying a significant operational scale.
- The company develops, manufactures, and markets both generic prescription and over-the-counter pharmaceuticals.
IPAH Healthcare Stock FAQ
What do analysts say about IPAH stock?
As of March 18, 2026, formal analyst ratings for Interpharm Holdings, Inc. (IPAH) are unavailable due to its listing on the OTC Other tier and limited coverage. Key valuation metrics such as P/E ratio (-0.02) and profit margin (-18.6%) suggest financial challenges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC Other tier status.
- Financial data based on available information as of March 18, 2026.